Amgen (AMGN) Launches Pavblu As Rival To Regeneron's (REGN) Eylea - Bloomberg
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Regeneron Pharma (REGN) PT Lowered to $1,175 at Evercore ISI
October 24, 2024 6:07 AM EDTEvercore ISI analyst Cory Kasimov lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $1,175.00 (from $1,250.00) while maintaining a Outperform rating.
The analyst comments "Were adjusting our REGN PT to $1175 to reflect an earlier bEylea launch. Shares are down ~18% since... More
Regeneron Pharma (REGN) PT Lowered to $1,050 at Wells Fargo
October 23, 2024 6:40 AM EDTWells Fargo analyst Mohit Bansal lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $1,050.00 (from $1,200.00) while maintaining a Overweight rating.
The analyst comments "What's new? The Federal Circuit Court has lifted its earlier temporary stay on AMGN launching its Eylea biosimilar. The... More
Regeneron (REGN) Weakness Tied to Report Court Rejects Request for Injunction for Eylea Generic
October 22, 2024 12:45 PM EDTRegeneron (NASDAQ: REGN) Weakness Tied to Report Court Rejects Request for Injunction for Eylea Generic
Shares down 4.5%... More
